Barinthus Biotherapeutics plc (BRNS)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Research and Development of Immunotherapies and Vaccines		14.97M	802.00K	44.70M	268.00K	4.82M
Research and Development of Immunotherapies and Vaccines Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%
Total		14.97M	802.00K	44.70M	268.00K	4.82M
Total Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United Kingdom		14.97M	802.00K	44.70M	268.00K	4.82M
United Kingdom Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%
Total		14.97M	802.00K	44.70M	268.00K	4.82M
Total Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%

Data Source: S&P Global Market Intelligence Last updated: Mar 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 26, 2026

Data Sources Report a data error